Dexcom (DXCM) Amortization of Deferred Charges (2016 - 2026)
Dexcom has reported Amortization of Deferred Charges over the past 12 years, most recently at $1.0 million for Q1 2026.
- Quarterly Amortization of Deferred Charges fell 47.37% to $1.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Mar 2026, down 14.67% year-over-year, with the annual reading at $7.3 million for FY2025, 2.67% down from the prior year.
- Amortization of Deferred Charges was $1.0 million for Q1 2026 at Dexcom, down from $1.7 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $2.2 million in Q3 2023 and troughed at $1.0 million in Q1 2026.
- The 5-year median for Amortization of Deferred Charges is $1.8 million (2024), against an average of $1.8 million.
- Year-over-year, Amortization of Deferred Charges surged 46.67% in 2023 and then plummeted 47.37% in 2026.
- A 5-year view of Amortization of Deferred Charges shows it stood at $1.6 million in 2022, then increased by 25.0% to $2.0 million in 2023, then decreased by 5.0% to $1.9 million in 2024, then decreased by 10.53% to $1.7 million in 2025, then tumbled by 41.18% to $1.0 million in 2026.
- Per Business Quant, the three most recent readings for DXCM's Amortization of Deferred Charges are $1.0 million (Q1 2026), $1.7 million (Q4 2025), and $1.9 million (Q3 2025).